ICU Medical’s (ICUI) “Hold” Rating Reiterated at Needham & Company LLC

Needham & Company LLC reaffirmed their hold rating on shares of ICU Medical (NASDAQ:ICUI) in a research report released on Wednesday,Benzinga reports.

Other equities research analysts also recently issued reports about the company. StockNews.com downgraded ICU Medical from a “buy” rating to a “hold” rating in a report on Tuesday. Jefferies Financial Group assumed coverage on ICU Medical in a research note on Monday, October 14th. They issued a “hold” rating and a $183.00 price objective for the company. KeyCorp increased their price objective on ICU Medical from $147.00 to $198.00 and gave the stock an “overweight” rating in a research note on Tuesday, October 15th. Finally, Raymond James increased their price objective on ICU Medical from $158.00 to $190.00 and gave the stock an “outperform” rating in a research note on Thursday, September 12th. Three research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $173.00.

ICU Medical Stock Performance

Shares of NASDAQ:ICUI traded down $4.10 on Wednesday, hitting $167.86. The company’s stock had a trading volume of 263,388 shares, compared to its average volume of 275,554. ICU Medical has a 12 month low of $82.82 and a 12 month high of $196.26. The company has a market capitalization of $4.11 billion, a price-to-earnings ratio of -36.73 and a beta of 0.66. The stock’s 50-day moving average is $176.43 and its two-hundred day moving average is $142.68. The company has a debt-to-equity ratio of 0.75, a quick ratio of 1.08 and a current ratio of 2.29.

ICU Medical (NASDAQ:ICUI) last announced its earnings results on Tuesday, November 12th. The medical instruments supplier reported $1.23 earnings per share for the quarter, beating the consensus estimate of $0.88 by $0.35. ICU Medical had a positive return on equity of 5.05% and a negative net margin of 4.74%. The business had revenue of $580.07 million during the quarter, compared to analysts’ expectations of $574.77 million. On average, equities research analysts forecast that ICU Medical will post 3.81 EPS for the current year.

Insider Transactions at ICU Medical

In other news, CEO Vivek Jain sold 12,000 shares of the stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $163.46, for a total transaction of $1,961,520.00. Following the transaction, the chief executive officer now owns 104,593 shares of the company’s stock, valued at approximately $17,096,771.78. This represents a 10.29 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, VP Daniel Woolson sold 2,502 shares of the stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $163.22, for a total value of $408,376.44. Following the transaction, the vice president now directly owns 13,107 shares in the company, valued at approximately $2,139,324.54. This represents a 16.03 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 38,502 shares of company stock valued at $6,573,496 in the last three months. Corporate insiders own 6.70% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Allworth Financial LP grew its holdings in ICU Medical by 100.0% in the 3rd quarter. Allworth Financial LP now owns 200 shares of the medical instruments supplier’s stock valued at $36,000 after buying an additional 100 shares during the last quarter. Xponance Inc. grew its holdings in ICU Medical by 6.0% in the 2nd quarter. Xponance Inc. now owns 1,977 shares of the medical instruments supplier’s stock valued at $235,000 after buying an additional 112 shares during the last quarter. Equitable Trust Co. grew its holdings in ICU Medical by 2.2% in the 3rd quarter. Equitable Trust Co. now owns 5,213 shares of the medical instruments supplier’s stock valued at $950,000 after buying an additional 112 shares during the last quarter. CWM LLC grew its holdings in ICU Medical by 18.5% in the 2nd quarter. CWM LLC now owns 767 shares of the medical instruments supplier’s stock valued at $91,000 after buying an additional 120 shares during the last quarter. Finally, Hexagon Capital Partners LLC grew its holdings in ICU Medical by 162.7% in the 3rd quarter. Hexagon Capital Partners LLC now owns 197 shares of the medical instruments supplier’s stock valued at $36,000 after buying an additional 122 shares during the last quarter. Institutional investors and hedge funds own 96.10% of the company’s stock.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.